Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apellis Pharmaceuticals (APLS), GW Pharma (GWPH) and Avanos Medical (AVNS).
Apellis Pharmaceuticals (APLS)
In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $78.00. The company’s shares closed last Tuesday at $33.47.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 13.1% and a 42.9% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Alexion Pharmaceuticals, and NGM Biopharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apellis Pharmaceuticals with a $53.60 average price target, a 68.4% upside from current levels. In a report issued on October 23, BMO Capital also maintained a Buy rating on the stock with a $59.00 price target.
See today’s analyst top recommended stocks >>
GW Pharma (GWPH)
In a report released today, Danielle Brill from Raymond James maintained a Hold rating on GW Pharma. The company’s shares closed last Tuesday at $108.21.
According to TipRanks.com, Brill is a 5-star analyst with an average return of 21.1% and a 58.8% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.
GW Pharma has an analyst consensus of Strong Buy, with a price target consensus of $173.75.
Avanos Medical (AVNS)
In a report released today, Lawrence Keusch from Raymond James maintained a Hold rating on Avanos Medical. The company’s shares closed last Tuesday at $40.32.
According to TipRanks.com, Keusch is a 4-star analyst with an average return of 4.1% and a 54.0% success rate. Keusch covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Intuitive Surgical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Avanos Medical with a $43.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
